Healthcare decision makers (HCDM) play a critical role in providing patients with access to high-quality, clinically validated digital therapeutics. Given the growth of the DTx industry over the last decade and lack of frameworks defining what “good” looks like, many HCDMs have needed to develop their own methods to evaluate DTx products.
DTA’s DTx Value Assessment & Integration Guide provides HCDMs and DTx manufacturers with an initial framework to assess DTx products, their value, and impact in real-world settings. With ongoing engagement from patients, clinicians, payors, and policy makers, this Guide will continue to be updated to ensure ongoing relevance in this quickly evolving ecosystem.
This Guide is designed to assist healthcare decision makers in assessing and integrating DTx products into clinical use settings. Target audiences for this Guide include:
This Guide is intended to serve as a conversation starter between HCDMs and DTx manufacturers. It does not provide a definitive decision for HCDMs on whether or not to use a specific product in practice, and does not imply that a product has or has not met all necessary qualifications for clinical use. DTA invites HCDMs to join our efforts in developing the next iterations of this framework.
The following topics covered in this Guide may benefit patients, clinicians, policy makers, and payors from around the world as they increasingly assess and use DTx therapies at scale:
Supporting the industry’s continuing evolution
This Guide was developed through a collaborative process, with input from DTA members, as well as clinicians, payors, and others involved in manufacturing, evaluating, supporting, and utilizing DTx products.
As the DTx ecosystem continues to rapidly evolve, this framework will be updated to ensure ongoing relevance with input from all key stakeholders. Please share insights with us on how you are using or implementing this Guide, or if you would like to be part of ongoing efforts.Share Your Insights
This resource is for educational purposes only and is not intended as legal advice to individual companies. Payors have
differing coverage, coding, and reimbursement policies. Laws, regulations, and payor policies concerning coverage, coding,
and reimbursement are complex and are evolving rapidly. For legal advice, please consult with legal counsel.
Digital Therapeutics Alliance makes no warranty or representation regarding the completeness, accuracy, or timeliness of the
information provided and makes no guarantee of coverage or reimbursement for any digital therapeutic product. Contact the
applicable payor for specific guidance regarding coverage, coding, and reimbursement guidelines.